| Literature DB >> 28693481 |
Pinar Kuecuekbalaban1, Tim Rostalski2, Silke Schmidt2, Holger Muehlan2.
Abstract
BACKGROUND: The Internet enables an unprecedented opportunity to access a broad range of self-tests (e.g. testing for HIV, cancer, hepatitis B/C), which can be conducted by lay consumers without the help of a health professional. However, there is only little knowledge about the determinants of the use of self-tests. Thus, the aims of this study were (1) to experimentally investigate the impact of situational and application-related characteristics on the intention to use a self-test (ST), compared to being tested by a health professional at home (HPH) or at a doctor's office (HPD), (2) to examine the applicability of social-cognitive health behaviour theories on self-testing, and (3) to explore the advantages of integrating technological affinity into social-cognitive health behaviour models to predict self-testing.Entities:
Keywords: Factorial survey; Health behaviour (theories); Self-diagnosis; Self-management; Self-testing
Mesh:
Year: 2017 PMID: 28693481 PMCID: PMC5504798 DOI: 10.1186/s12913-017-2394-x
Source DB: PubMed Journal: BMC Health Serv Res ISSN: 1472-6963 Impact factor: 2.655
Overview of situational and application-related vignette dimensions
| ST | HPH | HPD | |||||
|---|---|---|---|---|---|---|---|
| n | % | n | % | n | % | ||
| Application purpose | |||||||
| 1. Risk assessment | 43 | 12.8 | 98 | 20.5 | 67 | 15,5 | |
| 2. Early detection of a disease | 57 | 16.9 | 65 | 13.6 | 86 | 19.9 | |
| 3. Clinical diagnostics | 66 | 19.6 | 100 | 20.9 | 42 | 9.7 | |
| 4. Therapy diagnostics | 34 | 10.1 | 66 | 13.8 | 108 | 24.9 | |
| 5. Drug effect | 81 | 24.0 | 76 | 15.9 | 51 | 11.8 | |
| 6. Monitoring | 56 | 16.6 | 73 | 15.3 | 79 | 18.2 | |
| Seriousness of the situation | |||||||
| 1. Acute and life-threatening | 115 | 34.1 | 82 | 17.2 | 113 | 26.1 | |
| 2. Acute, but not life-threatening | 70 | 20.8 | 138 | 28.9 | 98 | 22.6 | |
| 3. Chronic, slowly advancing and life-threatening | 59 | 17.5 | 91 | 19.0 | 89 | 20.6 | |
| 4. Chronic, but not life-threatening | 93 | 27.6 | 167 | 34.9 | 133 | 30.7 | |
| Setting of the test | |||||||
| 1. Independently at home without the presence of a health professional | 337 | 27.0 | 0 | 0 | 0 | 0 | |
| 2. Tested by a health professional at home | 0 | 0 | 478 | 38.3 | 0 | 0 | |
| 3. Tested by a health professional in the doctor’s office/hospital | 0 | 0 | 0 | 0 | 433 | 34.7 | |
| Analysis and feedback | |||||||
| 1. Analysed automatically, and the result is displayed immediately | 56 | 16.6 | 105 | 22.0 | 94 | 21.7 | |
| 2. Transmitted automatically and only a conspicuous result is communicated by a health professional | 75 | 22.3 | 0 | 0 | 0 | 0 | |
| 3. Transmitted automatically and the result is communicated by a health professional | 125 | 37.1 | 0 | 0 | 0 | 0 | |
| 4. Transmitted automatically and the result is communicated in written form | 81 | 24.0 | 0 | 0 | 0 | 0 | |
| 5. Analysed in a laboratory and only a conspicuous result is communicated by a health professional | 0 | 0 | 167 | 34.9 | 130 | 30.0 | |
| 6. Analysed in a laboratory and the result is communicated by a health professional | 0 | 0 | 105 | 22.0 | 82 | 18.9 | |
| 7. Analysed in a laboratory and the result is communicated in written form | 0 | 0 | 101 | 21.1 | 127 | 29.3 | |
| Medical expertise of the tested person | |||||||
| 1. No | 112 | 33.2 | 126 | 26.4 | 148 | 34.2 | |
| 2. Unprofessional | 135 | 40.1 | 167 | 34.9 | 130 | 30.0 | |
| 3. Professional | 90 | 26.7 | 185 | 38.7 | 155 | 35.8 | |
| Emotional support | |||||||
| 1. Not present | 120 | 35.6 | 145 | 30.3 | 168 | 38.8 | |
| 2. Potentially available | 119 | 35.3 | 149 | 31.2 | 131 | 30.3 | |
| 3. Personally present | 98 | 29.1 | 184 | 38.5 | 134 | 30.9 | |
Fig. 1Example of a vignette
Multilevel model with vignette characteristics and the criterion “intention to use a test” separately for the groups ST, HPH, and HPD
| RI_Vall | ||||||
|---|---|---|---|---|---|---|
| ST | HPH | HPD | ||||
| Fixed effects | b | (SE) | b | (SE) | b | (SE) |
| intercept | 36.00*** | (7.03) | 43.68*** | (5.08) | 55.24*** | (4.48) |
| Vignette characteristics | ||||||
| Application purpose | ||||||
| Risk assessmentRefA | ||||||
| Clinical diagnostics | 0.68 | (6.31) | 6.29 | (3.54) | 5.86 | (5.08) |
| Drug effect | 1.08 | (6.50) | 8.53* | (3.67) | 9.58* | (4.64) |
| Early detection of a disease | −1.57 | (6.65) | 8.62* | (4.27) | 13.22*** | (3.86) |
| Monitoring | 6.40 | (6.47) | 7.93 | (4.19) | 11.78** | (4.20) |
| Therapy diagnostics | 6.50 | (7.74) | 8.98* | (3.89) | 5.86 | (5.08) |
| Seriousness of the situation | ||||||
| Acute and life-threateningRefB | ||||||
| Acute, but not life-threatening | 6.66 | (5.37) | 2.96 | (3.97) | −4.08 | (4.11) |
| Chronic, but not life-threatening | 6.67 | (5.60) | 3.44 | (3.87) | −0.096 | (3.59) |
| Chronic, slowly advancing and life-threatening | 2.30 | (5.51) | 6.19 | (4.30) | 2.00 | (3.99) |
| Analysis and feedback | ||||||
| Transmitted automatically and the result is communicated in written formRefC | ||||||
| Transmitted automatically and only a conspicuous result is communicated by a health professional | RefC-1.57 | (5.77) | ||||
| Transmitted automatically and the result is communicated by a health professional | RefC1.40 | (5.45) | ||||
| Analyzed in a laboratory and only a conspicuous result is communicated by a health professionalRefD | ||||||
| Analyzed automatically, and the result is displayed immediately | RefC-5.41 | (5.27) | RefD4.58 | (3.28) | RefD3.46 | (3.44) |
| Analyzed in a laboratory and the result is communicated in written form | RefD4.31 | (3.34) | RefD-1.75 | (3.25) | ||
| Analyzed in a laboratory and the result is communicated by a health professional | RefD6.21 | (3.53) | RefD5.68 | (3.55) | ||
| Medical expertise of the tested person | ||||||
| NoRefE | ||||||
| Unprofessional | 4.42 | (4.94) | 0.96 | (3.16) | 1.09 | (3.10) |
| Professional | 13.33** | (4.96) | 9.80** | (3.12) | 8.66** | (3.02) |
| Emotional support | ||||||
| Not presentRefF | ||||||
| Potentially available | 7.93 | (4.60) | 5.25 | (3.27) | 3.52 | (3.18) |
| Personally present | 8.64 | (4.87) | 9.71** | (3.14) | 1.76 | (3.66) |
| Random effects | ||||||
| δim (error variance between) | 268.22 | 303.78 | 227.83 | |||
| εij (error variance within) | 672.58 | 461.16 | 411.73 | |||
| Deviance | 3247.86 | 4468.87 | 3985.02 | |||
| NO / NG | 337/183 | 478/196 | 433/192 | |||
No = Number of observations/vignettes
NG = Number of groups/respondents
* p < 0.05, ** p < 0.01, *** p < 0.001
Multilevel models with vignette and respondent characteristics and the criterion “intention to use a test” separately for the groups ST, HPH, and HPD
| RI_Vall_P_TA | RI_Vall_Pall | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ST | HPH | HPD | ST | HPH | HPD | |||||||
| Fixed effects | b | (SE) | b | (SE) | b | (SE) | b | (SE) | b | (SE) | b | (SE) |
| intercept | 36.65*** | (6.94) | 43.69*** | (5.05) | 55.87*** | (4.44) | 48.71*** | 4.65 | 52.40*** | (3.91) | 59.42*** | (3.35) |
| Vignette characteristics | ||||||||||||
| Application purpose | ||||||||||||
| Risk assessmentRefA | ||||||||||||
| Clinical diagnostics | −0.30 | (6.24) | 6.41 | (3.53) | 5.10 | (5.05) | 2.10 | (4.17) | 3.90 | (2.70) | −2.21 | (3.80) |
| Drug effect | 0.91 | (6.42) | 8.57* | (3.66) | 9.12* | (4.60) | −1.29 | (4.27) | 2.69 | (2.82) | 2.05 | (3.48) |
| Early detection of a disease | −2.50 | (6.59) | 8.72* | (4.26) | 12.64** | (3.85) | 2.16 | (4.38) | 5.93 | (3.25) | 4.61 | (2.91) |
| Monitoring | 5.67 | (6.39) | 8.25* | (4.17) | 11.27** | (4.16) | 6.16 | (4.28) | 2.28 | (3.21) | 3.98 | (3.15) |
| Therapy diagnostics | 5.94 | (7.66) | 9.31* | (3.88) | 10.32** | (3.66) | −0.41 | (5.10) | 4.85 | (2.98) | 0.59 | (2.79) |
| Seriousness of the situation | ||||||||||||
| Acute and life-threateningRefB | ||||||||||||
| Acute, but not life-threatening | 8.25 | (5.33) | 2.46 | (3.95) | −3.16 | (4.08) | 1.02 | (3.56) | −1.53 | (3.05) | 0.83 | (3.09) |
| Chronic, but not life-threatening | 7.91 | (5.53) | 3.49 | (3.85) | 0.129 | (3.56) | 6.46 | (3.74) | 1.73 | (2.97) | 2.63 | (2.70) |
| Chronic, slowly advancing and life-threatening | 2.90 | (5.48) | 5.88 | (4.28) | 1.80 | (3.96) | 1.59 | (3.64) | 6.08 | (3.27) | 3.94 | (2.96) |
| Analysis and feedback | ||||||||||||
| Transmitted automatically and the result is communicated in written formRefC | ||||||||||||
| Transmitted automatically and only a conspicuous result is communicated by a health professional | RefC-3.44 | (5.72) | RefC-0.44 | (3.82) | ||||||||
| Transmitted automatically and the result is communicated by a health professional | RefC0.23 | (5.37) | RefC0.93 | (3.60) | ||||||||
| Analyzed in a laboratory and only a conspicuous result is communicated by a health professionalRefD | ||||||||||||
| Analyzed automatically, and the result is displayed immediately | RefC-5.94 | (5.20) | RefD5.02 | (3.27) | RefD3.11 | (3.41) | RefC-0.38 | (3.46) | RefD5.16* | (2.49) | RefD0.96 | (2.54) |
| Analyzed in a laboratory and the result is communicated in written form | RefD4.62 | (3.33) | RefD-1.80 | (3.22) | RefD3.87 | (2.54) | RefD-1.75 | (2.41) | ||||
| Analyzed in a laboratory and the result is communicated by a health professional | RefD6.17 | (3.53) | RefD6.41 | (3.53) | RefD1.90 | (2.71) | RefD5.30* | (2.64) | ||||
| Medical expertise of the tested person | ||||||||||||
| NoRefE | ||||||||||||
| Unprofessional | 5.06 | (4.88) | 0.78 | (3.15) | 1.37 | (3.07) | 2.39 | (3.24) | 1.18 | (2.41) | −0.85 | (2.30) |
| Professional | 13.80** | (4.89) | 9.43** | (3.11) | 8.36** | (2.99) | 7.17* | (3.27) | 7.04** | (2.38) | 2.92 | (2.26) |
| Emotional support | ||||||||||||
| Not presentRefF | ||||||||||||
| Potentially available | 7.46 | (4.56) | 5.44 | (3.27) | 2.72 | (3.16) | 3.76 | (3.05) | 2.54 | (2.50) | 4.11 | (2.36) |
| Personally present | 8.61 | (4.81) | 9.66** | (3.13) | 0.94 | (3.63) | 3.78 | (3.19) | 4.41 | (2.41) | 4.70 | (2.72) |
| Respondent characteristics | ||||||||||||
| Technology affinity enthusiasm | 6.21* | (2.90) | 2.14 | (2.50) | 2.41 | (2.35) | 2.07 | (2.02) | 0.54 | (1.92) | 3.24 | (1.71) |
| Technology affinity competence | 0.16 | (3.20) | 2.29 | (2.97) | −1.02 | (2.64) | 2.07 | (2.26) | 2.87 | (2.31) | −2.50 | (1.95) |
| Technology affinity positive attitude | 4.04 | (3.60) | 4.79 | (3.01) | 7.29* | (3.01) | 0.17 | (2.48) | 2.11 | (2.31) | −0.43 | (2.22) |
| Perceived susceptibility | 0.24 | (0.34) | 0.37 | (0.33) | 0.40 | (0.31) | ||||||
| Self-efficacy | −0.04 | (0.31) | −0.51 | (0.31) | 0.07 | (0.27) | ||||||
| Perceived severity | 0.16*** | (0.04) | 0.23*** | (0.04) | 0.19*** | (0.03) | ||||||
| Outcome expectancy | 0.89*** | (0.05) | 0.68*** | (0.04) | 0.69*** | (0.04) | ||||||
| Random effects | ||||||||||||
| δim (error variance between) | 216.28 | 278.52 | 213.94 | 113.18 | 162.74 | 101.95 | ||||||
| εij (error variance within) | 676.11 | 461.75 | 406.46 | 286.40 | 267.99 | 230.54 | ||||||
| Deviance | 3234.43 | 4459.54 | 3974.44 | 2959.49 | 4200.21 | 3712.40 | ||||||
| NO / NG | 337/183 | 478/196 | 433/192 | 337/183 | 478/196 | 433/192 | ||||||
N Number of observations/vignettes
N Number of groups/respondents
* p < 0.05, ** p < 0.01, *** p < 0.001